Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients

Ingram, M. A., Lauren, B. N., Pumpalova, Y., Park, J., Lim, F., Bates, S. E., Kastrinos, F., Manji, G. A., Kong, C. Y., & Hur, C. (2022). Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 5(9). Portico. https://doi.org/10.1002/cnr2.1565
Authors:
Myles A Ingram
Brianna N Lauren
Yoanna Pumpalova
Jiheum Park
Francesca Lim
Susan E Bates
Fay Kastrinos
Gulam A Manji
Chung Yin Kong
Chin Hur
Affiliated Authors:
Myles A Ingram
Brianna N Lauren
Yoanna Pumpalova
Jiheum Park
Francesca Lim
Susan E Bates
Fay Kastrinos
Gulam A Manji
Chin Hur
Columbia Affiliation:
Subjects:
Pancreatic Cancer Research and Treatment (OpenAlex Topic)
Renal Cell Carcinoma (OpenAlex Topic)
Cholangiocarcinoma (OpenAlex Topic)
Carcinoma, Pancreatic Ductal (MeSH)
Pancreatic Neoplasms (MeSH)
Author Keywords:
chemotherapy
clinical cancer research
pancreatic cancer
elink
Publication Type:
Article
Unique ID:
10.1002/cnr2.1565
PMID:
35122419
DOI:
10.1002/cnr2.1565
Journal:
Cancer Reports
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View OpenAlex Record
View Web of Science Record

Record Created: